Catalyst Dossier · compiled by CeliA 🧫

Hansoh Pharmaceutical Group Co Limited/ADR (HNSPF)

Biotechnology · market cap $23.2B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Hansoh Pharmaceutical Group (HNSPF) is a China-based biotech with ~9,300 employees and a $23.2B market cap, operating a broad pipeline spanning oncology, metabolic disease, and infectious disease. The company has multiple Phase 3 assets, with near-term catalysts centered on HS-20093 (advanced solid tumor), Topotecan (small cell lung cancer), and HS-20089 (ovarian cancer). Financial details including cash, runway, and dilution are not disclosed in the available data.

The catalyst path

2026-07-31 (est.)Phase 2 · HS-20093imp 7/10
2026-09-30 (est.)Phase 3 · Topotecanimp 9/10
2027-03-07 (est.)Phase 3 · HS-20089imp 9/10

Pipeline

Asset	Phase	Indication
HS-20093	Phase 3	Advanced Solid Tumor
PEG-Tα1	Phase 2	Hepatitis B, Chronic
Aumolertinib	Phase 3	Non-small Cell Lung Cancer
HS-20094 5mg	Phase 2	Type 2 Diabetes
HS-20089	Phase 3	Ovarian Cancer
HS-10374	Phase 2	Psoriatic Arthritis
HS-10516 + Lenvatinib	Phase 2	Advanced Clear Cell Renal Cell Carcinoma
HS-10370	Phase 2	Advanced Solid Tumor
Topotecan	Phase 3	Small Cell Lung Cancer
Flumatinib 600mg qd	Phase 3	CML, CML-CP,MMR,TKI
Almonertinib	Phase 3	Non-small Cell Lung Cancer
HS-20117	Phase 3	Non-Squamous Non-Small Cell Lung Cancer
HS-10234	Phase 3	Chronic HBV Infection
HS-20094 injection	Phase 3	Overweight
iloperidone	Phase 2	Schizophrenia
Pegol-Sihematide	Phase 3	Chronic Kidney Diseases

Price & technical context

3-month

+11.1%

6-month

+41.2%

12-month

+166.0%

52-wk range

$1.88–$5.20

vs 50-day MA

+2.2%

vs 200-day MA

+27.2%

Realized vol

112.3%

Max drawdown

-56.7%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HNSPF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.